Usefulness of Carbohydrate Antigen 19-9 Test in Healthy People and Necessity of Medical Follow-up in Individuals with Elevated Carbohydrate Antigen 19-9 Level

Background Carbohydrate antigen 19-9 (CA 19-9) is a tumor marker whose level is elevated in many types of cancers and other benign conditions. CA 19-9 levels are frequently found to be elevated in individuals during general health examinations. This study aimed to investigate the clinical characteristics of such individuals and to determine the need for medical follow-up. Methods We investigated individuals who underwent a health inspection, including a serum CA 19-9 test, at our center. Their CA 19-9 levels, age, sex, body mass index (BMI), and personal and past histories were investigated. Additionally, subgroup analyses were performed for those who underwent follow-up study for the elevated CA 19-9 levels. Results Of 58,498 subjects, 581 (1.0%) had elevated CA 19-9 levels. Multivariate analyses revealed that older age, female sex, lower BMI, and diabetes were independent predisposing factors for elevated CA 19-9 level. A subgroup analysis revealed that the causative conditions were identified in 129 of 351 subjects (36.8%). Among them, the causative conditions in 31 subjects (8.8%, including four cases of cancer and 15 of benign tumors) were not detected at the initial check-up and were found during the follow-up period. Conclusion The use of CA 19-9 as a marker for cancer in healthy individuals is inappropriate. However, medical follow-up in individuals with elevated CA 19-9 levels may be useful because some causative diseases may be detected during follow-up.

[1]  M. Joo,et al.  Usefulness of CA 19-9 for pancreatic cancer screening in patients with new-onset diabetes. , 2018, Hepatobiliary & pancreatic diseases international : HBPD INT.

[2]  H. Heerkens,et al.  Systematic review on the role of serum tumor markers in the detection of recurrent pancreatic cancer. , 2018, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[3]  C. Sohn,et al.  Serum CEA and CA 19-9 Levels are Associated with the Presence and Severity of Colorectal Neoplasia , 2017, Yonsei medical journal.

[4]  Hsin-Yao Wang,et al.  Cancers Screening in an Asymptomatic Population by Using Multiple Tumour Markers , 2016, PloS one.

[5]  Honghe Zhang,et al.  Tumor markers CA19-9, CA242 and CEA in the diagnosis of pancreatic cancer: a meta-analysis. , 2015, International journal of clinical and experimental medicine.

[6]  O. Lavie,et al.  CA 19-9 in Evaluation of adnexal mass: retrospective cohort analysis and review of the literature , 2015, The International journal of biological markers.

[7]  P. Maisonneuve,et al.  Diabetes, Smoking, Alcohol Use, and Family History of Cancer as Risk Factors for Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis , 2015, Neuroendocrinology.

[8]  Se Hyung Kim,et al.  Elevated serum CA 19-9 at screening tests: underlying conditions and role of abdominopelvic CT , 2014, European Radiology.

[9]  Zhenya Song,et al.  Study of an elevated carbohydrate antigen 19-9 concentration in a large health check-up cohort in China , 2013, Clinical chemistry and laboratory medicine.

[10]  J. Rhee,et al.  How do we interpret an elevated carbohydrate antigen 19-9 level in asymptomatic subjects? , 2009, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[11]  A. Mayadağlı,et al.  Type 2 diabetes mellitus and CA 19-9 levels. , 2007, World journal of gastroenterology.

[12]  A. Siriwardena,et al.  Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. , 2007, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[13]  Z. Yue,et al.  Serum tumour markers in patients with chronic kidney disease , 2007, Scandinavian journal of clinical and laboratory investigation.

[14]  Daniel F Hayes,et al.  ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J. Magnani The discovery, biology, and drug development of sialyl Lea and sialyl Lex. , 2004, Archives of biochemistry and biophysics.

[16]  J. K. Lee,et al.  Clinical usefulness of carbohydrate antigen 19‐9 as a screening test for pancreatic cancer in an asymptomatic population , 2004, Journal of gastroenterology and hepatology.

[17]  Greg L Perkins,et al.  Serum tumor markers. , 2003, American family physician.

[18]  S. Myung,et al.  A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve , 1999, American Journal of Gastroenterology.

[19]  T. Homma,et al.  CA19‐9 as a Screening and Diagnostic Tool in Symptomatic Patients: The Japanese Experience , 1994, Pancreas.

[20]  K. Migita,et al.  Elevation of a tumor associated antigen CA 19-9 levels in patients with rheumatic diseases. , 1989, The Journal of rheumatology.

[21]  T. Frebourg,et al.  The evaluation of CA 19‐9 antigen level in the early detection of pancreatic cancer: A prospective study of 866 patients , 1988, Cancer.

[22]  Qiwen Ben,et al.  The relationship between new-onset diabetes mellitus and pancreatic cancer risk: a case-control study. , 2011, European journal of cancer.

[23]  J. Yim,et al.  Increased CA 19-9 level in patients without malignant disease , 2009, Clinical Chemistry and Laboratory Medicine.